Alvotech Receives CRL From FDA Over Ustekinumab Filing

Knockback For Stelara Biosimilar Comes After CRLs For Adalimumab Candidate

 
• By David Wallace
Sign outside of FDA's headquarters in White Oak, MD
The FDA issued a complete response letter over the AVT04 candidate • Source: Alamy

More from Biosimilars

More from Products